Skip to content
Screener

Capricor Therapeutics CAPR Business Segments — General And Administrative Expense

Similar metrics at other companies

Alumis Inc. logo
ALMSSingle Reportable — General And Administrative Expense
$18.61M-16.5%
Immunome logo
IMNMSingle Reportable — General And Administrative Expense
-$8.65M-17.3%
ALO
ALOVSingle Reportable — General And Administrative Expense
-$658.46K
Research Solutions logo
RSSSSingle Reportable — General And Administrative Expense
$1.63M-11.9%
Ur-Energy logo
URGSingle Reportable — General And Administrative Expense
$3.92M+80.5%
Dogwood Therapeutics logo
DWTXSingle Reportable — General And Administrative Expense
$2.41M+20.8%

Other financials

Income statement

See full
Revenue--100%
Operating income-$36.8M-47.2%
Net income-$33.9M-39.2%
EPS (diluted)-$0.59-11.3%

Balance sheet

See full
Cash & equivalents$105.4M+266%
Total debt$14.8M+1,083%
Total equity$278.7M+118%
Total assets$326.3M+112%

Cash flow

See full
Operating cash flow-$29.3M-355%
CapEx$5.1M+472%
Free cash flow-$34.4M-369%

Valuation

See full
Market cap$242.07M-31.6%
Enterprise value$151.43M-54.3%

Profitability

See full
Operating margin-778.8%-1,038pp
Net margin-736.6%-981pp
FCF margin-563.9%-954pp

Returns & leverage

See full
Return on equity-56.4%-11.3pp
Debt / equity0.1×0.0×
Current ratio8.4×+1.9×

Where this comes from

Reported directly by Capricor Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The source filing: Capricor Therapeutics’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 5:20 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-060382
Total revenueThree months ended March 31, 2026 / —Three months ended March 31, 2025 / —
Total general and administrative expense, excluding non-cash expense6,350,7122,876,076
Stock-based compensation expense2,791,8743,000,814
Depreciation and amortization253,355190,486
Total general and administrative expense9,395,9416,067,376
Operating loss(36,772,853)(24,982,948)
Investment income2,904,506729,542
Other income (expense)(72,998)(138,188)
Total non-operating income, net2,831,508591,354

Item 1. Financial Statements.

FAQ

What is Capricor Therapeutics's business segments — general and administrative expense?
Capricor Therapeutics (CAPR) reported business segments — general and administrative expense of $9.4M in Q1 2026.
How has Capricor Therapeutics's business segments — general and administrative expense changed year-over-year?
Capricor Therapeutics's business segments — general and administrative expense increased by 54.9% year-over-year, from $6.07M to $9.4M.
What does business segments — general and administrative expense mean?
This metric represents the total aggregate costs incurred for the administrative, legal, and corporate support functions of the business segment. It serves as a measure of the overhead required to manage the company's operations and regulatory compliance. Controlling these expenses is vital for preserving capital in early-stage biotechnology companies.

Ask your AI about Capricor Therapeutics's business segments — general and administrative expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude